Cargando…

Mismatch Negativity and Cognitive Performance for the Prediction of Psychosis in Subjects with At-Risk Mental State

BACKGROUND: A shorter duration of untreated psychosis has been associated with better prognosis in schizophrenia. In this study, we measured the duration mismatch negativity (dMMN), an event-related potential, and cognitive performance in subjects with at-risk mental state (ARMS), patients with firs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Higuchi, Yuko, Sumiyoshi, Tomiki, Seo, Tomonori, Miyanishi, Tomohiro, Kawasaki, Yasuhiro, Suzuki, Michio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547932/ https://www.ncbi.nlm.nih.gov/pubmed/23349791 http://dx.doi.org/10.1371/journal.pone.0054080

Ejemplares similares

Mismatch Negativity and P3a/Reorienting Complex in Subjects with Schizophrenia or At-Risk Mental State
por: Higuchi, Yuko, et al.
Publicado: (2014)

LORETA Current Source Density for Duration Mismatch Negativity and Neuropsychological Assessment in Early Schizophrenia
por: Miyanishi, Tomohiro, et al.
Publicado: (2013)

Electrophysiological and Neuropsychological Predictors of Conversion to Schizophrenia in At-Risk Subjects
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version
por: Higuchi, Yuko, et al.
Publicado: (2017)

Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia
por: Higuchi, Yuko, et al.
Publicado: (2021)

Analysis of polyunsaturated fatty acids in antipsychotic-free individuals with at-risk mental state and patients with first-episode schizophrenia
por: Le, Anh Thi Phuong, et al.
Publicado: (2023)

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes
por: Omachi, Yoshie, et al.
Publicado: (2018)

Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients
por: Nakajima, Suguru, et al.
Publicado: (2021)

Successful Treatment with Olanzapine of Psychosis in Dentatorubral-pallidoluysian Atrophy: A Case Report
por: Narita, Zui, et al.
Publicado: (2018)

Successful treatment of psychosis in dentatorubral‐pallidoluysian atrophy with quetiapine: A case report
por: Narita, Zui, et al.
Publicado: (2018)

Forecasting prognostic trajectories with mismatch negativity in early psychosis
por: Kim, Minah, et al.
Publicado: (2023)

Pituitary Volume and Socio-Cognitive Functions in Individuals at Risk of Psychosis and Patients With Schizophrenia
por: Takahashi, Tsutomu, et al.
Publicado: (2018)

Editorial: Cognitive Enhancement in Psychiatric Disorders
por: Sumiyoshi, Tomiki, et al.
Publicado: (2019)

PM510. Temporal relationship of mismatch negativity multiple generators in patients with schizophrenia and subjects at clinical high risk for psychosis
por: Kim, Minah, et al.
Publicado: (2016)

Mismatch negativity generation in subjects at risk for psychosis: source analysis is more sensitive than surface electrodes in risk prediction
por: Aeberli, Tina, et al.
Publicado: (2023)

Reduced duration mismatch negativity in adolescents with psychotic symptoms: further evidence for mismatch negativity as a possible biomarker for vulnerability to psychosis
por: Murphy, Jennifer R, et al.
Publicado: (2013)

Early Intervention and a Direction of Novel Therapeutics for the Improvement of Functional Outcomes in Schizophrenia: A Selective Review
por: Kurachi, Masayoshi, et al.
Publicado: (2018)

Cognitive Deficits in Schizophrenia and Other Neuropsychiatric Disorders: Convergence of Preclinical and Clinical Evidence
por: Stuchlik, Ales, et al.
Publicado: (2014)

Reduced Hippocampal Subfield Volume in Schizophrenia and Clinical High-Risk State for Psychosis
por: Sasabayashi, Daiki, et al.
Publicado: (2021)

F14. REDUCED DURATION MISMATCH NEGATIVITY ASSOCIATED WITH DECREASED GLUTAMATE+GLUTAMINE LEVEL IN SUBJECTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
por: Tang, Yingying, et al.
Publicado: (2018)

Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity
por: Ranlund, Siri, et al.
Publicado: (2015)

Financial debt, worry about debt and mental health in Japan
por: Stickley, Andrew, et al.
Publicado: (2023)

Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2014)

Mismatch Negativity (MMN) response studies in elderly subjects
por: Buranelli, Gabriela, et al.
Publicado: (2015)

T-817MA, but Not Haloperidol and Risperidone, Restores Parvalbumin-Positive γ-Aminobutyric Acid Neurons in the Prefrontal Cortex and Hippocampus of Rats Transiently Exposed to MK-801 at the Neonatal Period
por: Uehara, Takashi, et al.
Publicado: (2012)

Mismatch Negativity Latency and Cognitive Function in Schizophrenia
por: Kärgel, Christian, et al.
Publicado: (2014)

Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
por: Nagai, Tatsuya, et al.
Publicado: (2017)

Mismatch Negativity Predicts Remission and Neurocognitive Function in Individuals at Ultra-High Risk for Psychosis
por: Fujioka, Mao, et al.
Publicado: (2020)

Premorbid intellectual ability in schizophrenia influence family appraisal related to cognitive impairments: a cross-sectional study on cognitive impairment and family assessments
por: Ebina, Kota, et al.
Publicado: (2022)

Competence to Consent and Its Relationship With Cognitive Function in Patients With Schizophrenia
por: Sugawara, Norio, et al.
Publicado: (2019)

Verification of the Mismatch Negativity (MMN) responses in normal adult subjects
por: Bortoleto Brossi, Adriana, et al.
Publicado: (2015)

Anatomical variations in the insular cortex in individuals at a clinical high-risk state for psychosis and patients with schizophrenia
por: Takahashi, Tsutomu, et al.
Publicado: (2023)

Are attention-deficit/hyperactivity disorder symptoms associated with negative health outcomes in individuals with psychotic experiences? Findings from a cross-sectional study in Japan
por: Stickley, Andrew, et al.
Publicado: (2023)

New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
por: Jeon, Won Je, et al.
Publicado: (2015)

Mismatch Negativity as a “Translatable” Brain Marker Toward Early Intervention for Psychosis: A Review
por: Nagai, Tatsuya, et al.
Publicado: (2013)

F153. NEUROMAGNETIC MISMATCH NEGATIVITY IN CLINICAL HIGH RISK AND FIRST-EPISODE PSYCHOSIS INDIVIDUALS
por: Mikanmaa, Emmi, et al.
Publicado: (2018)

Mismatch Negativity and Impaired Social Functioning in Long-Term and in First Episode Schizophrenia Spectrum Psychosis
por: Murphy, Timothy K., et al.
Publicado: (2020)

Progressive Impairment of Mismatch Negativity Is Reflective of Underlying Pathophysiological Changes in Patients With First-Episode Psychosis
por: Lho, Silvia Kyungjin, et al.
Publicado: (2020)

S137. LEFT HEMISPHERE MEG DEFICIT IN PITCH AND DURATION MISMATCH NEGATIVITY IN FIRST EPISODE PSYCHOSIS
por: Duricy, Erin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m6ut8g6gqmnv6mfml9oqrvvd66